Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com

Businesswire01:41

Based On Its ROE, Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A High Quality Stock?

Simply Wall StDec 10 18:05

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?

Yahoo FinanceDec 7 00:31

Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.

Dow JonesDec 3 20:09 · Ratings

Sarepta Therapeutics Analyst Ratings

BenzingaDec 3 19:56 · Ratings

H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75

Futu NewsDec 2 23:32 · Ratings